High Versus Low Dose Nitroglycerin in Acute Pulmonary Edema

Pulmonary Edema Clinical Trial

Official title:

High Versus Low Dose Nitroglycerin in Management of Sympathetic Crashing Acute Pulmonary Edema

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

• NCT number: NCT06107465
• Other study ID #: 0108016
• Status: Enrolling by invitation
• Phase: Phase 2/Phase 3
• Start date: November 10, 2023
• Est. completion date: July 2024

Study information

• Verified date: October 2023
• Source: Alexandria University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this randomized controlled trial is evaluate the out come of:

• Low dose (< 100 mic/min )versus

• High dose (> 100 mic/min) of nitroglycerin in management of patients with acute pulmonary edema presented to Emergency Department of Alexandria University Hospitals.

The main questions it aims to answer is:

• Time of resolution of high blood pressure, hypoxia, tacchypnea

• Need for invasive mechanical ventilation, ICU admission

Description:

This single blind parallel randomized controlled trial will be conducted on (30 patients in each group) presented to Alexandria University Hospitals with acute pulmonary edema defined as: acute onset of dyspnea < 6 hrs, tacchypnea ( respiratory rate ≥30 breaths/min), bilaterak crepitations, O2 saturation < 90% on room air with associted sympathetic surge recognized by presence of tacchycardia, agitationa and blood pressure ≥ 160/90 mmHg

All patients included in the study will be allocated randomly using computer software with concealment of randomization in to two groups:

• Group (A): Low dose group Nitroglycerin at will be initiated at a rate <100 mic/min (15)

• Group (B): high dose group Initial dose > 100 mic /min (15) will be started Blood pressure will be measured for both groups every 15 minutes and dose adjusted accordingly, if the blood pressure starts to decrease continue infusion rate. In case of rising or constant blood pressure increase nitroglycerin by 20 mic/min every 15 min till blood pressure starts to decrease.

Initial, peak rate within the first hour, duration of IV nitroglycerin infusion will be recorded in both groups.

Initial and maximum dose of loop diuretic will be recorded in both groups.

Outcome:

Patients will be followed during ED stay to compare the two groups as regard:

• Time of resolution of high blood pressure.

• Resolution of hypoxia.

• Resolution of tachypnea.

• Need for invasive mechanical ventilation.

• Need for ICU admission.

• Length of hospital stay.

• Incidence of drug side effects as hypotension.

• Mortality.

Recruitment information / eligibility

• Status: Enrolling by invitation
• Enrollment: 60
• Est. completion date: July 2024
• Est. primary completion date: June 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• All adult patients (> 18 years) presented with sympathetic crashing acute pulmonary edema.

Exclusion Criteria:

1 - Patients indicated for emergency endotracheal intubation. 2-Patients with history of nitroglycerin allergy. 3-Preload dependent patients as patients with aortic stenosis. 4-Drug interaction with nitroglycerin as sildenafil, ergots. 5-Patients indicated for emergency percutaneous intervention.

Related Conditions & MeSH terms

• Edema
• Pulmonary Edema

Intervention

Drug:
• Nitroglycerin
high dose Nitroglycerin

Locations

Country	Name	City	State
Egypt	Alexandria University, Faculty of Medicine	Alexandria

Sponsors (1)

Lead Sponsor	Collaborator
Alexandria University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Resolution of symptoms	( hypoxia, high blood pressure and tacchypnea )	approximately 6 months